Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology/Urology
Disease Category: Kidney Disease

Trial Information

Kidney Disease Study CSBR759A2201

Novartis is conducting this clinical research study to find out if the study drug is better than sevelamer HCl at reducing phosphate levels in the blood of participants on dialysis. This study drug is an investigational drug, which means it is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Total participation in this study will last for about 12 months. There will be a total of 28 study visits. All will take place during the first dialysis treatment of the week. The first 16 visits and the last 2 visits will occur weekly and all others only once a month.
www.NovartisClinicalTrials.com

Research Center
Located In:
Various Cities, CA

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.